Related Experiment Video

Updated: May 29, 2026

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer

Christopher H Switzer1, Sharon A Glynn, Lisa A Ridnour

  • 1Radiation Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Trends in Pharmacological Sciences
|September 7, 2011
PubMed

Insights

Inducible nitric oxide synthase (NOS2) promotes aggressive estrogen receptor-negative breast cancer. Activating protein phosphatase 2A (PP2A) may counteract this tumor-promoting signaling, offering a new therapeutic strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Basal-like breast cancer, often triple-negative, presents aggressive behavior and limited treatment options.
  • Inducible nitric oxide synthase (NOS2) is a key predictor of survival in estrogen receptor-negative (ER[-]) breast cancer and correlates with a basal-like phenotype.
  • Nitric oxide (NO) signaling pathways, including ERK-1/2, PI3K/Akt, and c-Myc, are implicated in promoting cancer progression.

Purpose of the Study:

  • To investigate the roles of nitric oxide (NO) and protein phosphatase 2A (PP2A) in estrogen receptor-negative (ER[-]) breast cancer.
  • To propose a novel mechanism where PP2A activation antagonizes NO-driven pro-tumor signaling.
  • To explore the therapeutic potential of targeting NO and PP2A pathways in ER[-] breast cancer.

Main Methods:

  • Review and synthesis of existing literature on NO and PP2A functions in breast cancer.
  • Analysis of signaling pathways regulated by NO and PP2A.
  • Examination of potential pharmacological agents to modulate PP2A activity in ER[-] breast cancer cells.

Main Results:

  • NOS2 expression is linked to poor survival and a basal-like phenotype in ER[-] breast cancer.
  • NO activates oncogenic signaling pathways (ERK-1/2, PI3K/Akt, c-Myc) that drive cancer progression.
  • PP2A, a tumor suppressor, negatively regulates these same pathways, but its activity is suppressed in tumor cells.

Conclusions:

  • PP2A activation presents a potential therapeutic strategy to counteract NO-mediated tumor promotion in ER[-] breast cancer.
  • Understanding the interplay between NO and PP2A is crucial for developing novel treatments for aggressive breast cancer subtypes.
  • Targeting PP2A may offer a novel mechanism to inhibit pro-tumor signaling pathways activated by NO in ER[-] breast cancer.

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...